WO2006040779A3 - Controlled release gastric floating matrix formulation containing imatinib - Google Patents

Controlled release gastric floating matrix formulation containing imatinib Download PDF

Info

Publication number
WO2006040779A3
WO2006040779A3 PCT/IN2005/000333 IN2005000333W WO2006040779A3 WO 2006040779 A3 WO2006040779 A3 WO 2006040779A3 IN 2005000333 W IN2005000333 W IN 2005000333W WO 2006040779 A3 WO2006040779 A3 WO 2006040779A3
Authority
WO
WIPO (PCT)
Prior art keywords
controlled release
formulation containing
gastric floating
matrix formulation
floating matrix
Prior art date
Application number
PCT/IN2005/000333
Other languages
French (fr)
Other versions
WO2006040779A2 (en
Inventor
Durga Maheswari Parvataneni
Appala Swamy Naidu Rongala
Khadgapathi Podile
Chowdary Nannapaneni Venkaiah
Original Assignee
Natco Pharma Ltd
Durga Maheswari Parvataneni
Appala Swamy Naidu Rongala
Khadgapathi Podile
Chowdary Nannapaneni Venkaiah
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd, Durga Maheswari Parvataneni, Appala Swamy Naidu Rongala, Khadgapathi Podile, Chowdary Nannapaneni Venkaiah filed Critical Natco Pharma Ltd
Publication of WO2006040779A2 publication Critical patent/WO2006040779A2/en
Publication of WO2006040779A3 publication Critical patent/WO2006040779A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical formulation and its process for the preparation of controlled release gastric floating matrix solid oral dosage form of Imatinib or its pharmaceutically acceptable salts and its polymorphs such as β, α2, Form I and Form 2 thereof for once daily administration in the form of coated tablet or minitablets and / or pellets filled in hard gelatin capsules.
PCT/IN2005/000333 2004-10-11 2005-10-06 Controlled release gastric floating matrix formulation containing imatinib WO2006040779A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1049CH2004 2004-10-11
IN1049/CHE/2004 2004-10-11

Publications (2)

Publication Number Publication Date
WO2006040779A2 WO2006040779A2 (en) 2006-04-20
WO2006040779A3 true WO2006040779A3 (en) 2006-08-17

Family

ID=36148723

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2005/000333 WO2006040779A2 (en) 2004-10-11 2005-10-06 Controlled release gastric floating matrix formulation containing imatinib

Country Status (1)

Country Link
WO (1) WO2006040779A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
WO2007106957A1 (en) * 2006-03-21 2007-09-27 Laboratoires Smb S.A. Multiple units controlled-release floating dosage forms
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
CA2680249A1 (en) * 2007-03-12 2008-09-18 Dr. Reddy's Laboratories, Inc. Imatinib mesylate
FR2918566B1 (en) 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa STABLE PHARMACEUTICAL COMPOSITION OF A WATER SOLUBLE SALT OF VINFLUNINE.
US20090087489A1 (en) 2007-09-25 2009-04-02 Bella Gerber Imatinib compositions
EP2255792A1 (en) * 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
CZ2009570A3 (en) 2009-08-26 2011-03-09 Zentiva, K. S. Preparation, stabilization and use of imatinib mesylate polymorphs for development of medicinal forms
MX2013001653A (en) 2010-08-11 2013-05-22 Synthon Bv Pharmaceutical granulate comprising imatinib mesylate
WO2012080703A1 (en) * 2010-12-15 2012-06-21 Cipla Limited Pharmaceutical composition comprising imatinib
US9750700B2 (en) * 2011-06-22 2017-09-05 Natco Pharma Limited Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
WO2014041551A1 (en) 2012-09-14 2014-03-20 Natco Pharma Limited Formulation comprising imatinib as oral solution
US20150110871A1 (en) * 2014-06-02 2015-04-23 David Wong Gastric retentive tablet compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090720A1 (en) * 2002-04-23 2003-11-06 Novartis Ag High drug load tablet
WO2003090750A1 (en) * 2002-04-24 2003-11-06 Board Of Regents, The University Of Texas System Pdgf receptor tyrosine kinase inhibitors for the treatment of polycythemia vera

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090720A1 (en) * 2002-04-23 2003-11-06 Novartis Ag High drug load tablet
WO2003090750A1 (en) * 2002-04-24 2003-11-06 Board Of Regents, The University Of Texas System Pdgf receptor tyrosine kinase inhibitors for the treatment of polycythemia vera

Also Published As

Publication number Publication date
WO2006040779A2 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
WO2006040779A3 (en) Controlled release gastric floating matrix formulation containing imatinib
US10512621B2 (en) Methods of treating posttraumatic stress disorder with acamprosate salts
FI97686C (en) Process for producing barley for the manufacture of controlled release products
WO2001056544A3 (en) Shell-and-core dosage form approaching zero-order drug release
CN102065847A (en) Pharmaceutical formulation containing angiotensin-II receptor blocker
BR0012981A (en) Hydrodynamically Balanced Oral Drug Release System
WO2002028376A3 (en) Chrono delivery formulations and method of use thereof
US20150250746A1 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
NO20084065L (en) Quick-release paracetamol tablets
CA2065652A1 (en) Controlled release gastroresistant pharmaceutical formulations for oral administration containing bile acids and their salts
WO2007122635A3 (en) Controlled release formulation comprising anti-epileptic drugs
WO2007031887A3 (en) Extended release pharmaceutical composition of metformin and a process for producing it
HUP0004966A3 (en) Pharmaceutical composition for oral administration in the form of matrix tablet enabling the prolonged release of trimetazidine
WO2002024203A3 (en) Controlled release formulations for oral administration
HK1067299A1 (en) Pharmaceutical compositions containing terbinafineand use thereof
WO2007086079A3 (en) Sustained release dosage form of phenothiazine derivatives containing channelizer
CN104379138B (en) Acamprosate formulations, methods of use thereof, and combinations comprising acamprosate formulations
WO2004062552A3 (en) Pharmaceutical composition containing a nsaid and a benzimidazole derivative
CA2516327A1 (en) Therapeutic system comprising amoxicillin and clavulanic acid
WO2009014372A3 (en) Dispersible tablet comprising coated drug-containing particles and method for the preparation thereof
WO2005013935A3 (en) Composition for releasing a weak base for an extended period of time
WO2018206923A1 (en) Novel formulations
US20070009599A1 (en) Asymmetrically coated table
WO2004089333A3 (en) A stable benzimidazole formulation
CN101869708A (en) Medicament composition containing calcium channel blockers and biguanide antidiabetic medicine and application thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase